Data Mining Techniques Could Improve Cancer Gene Therapies

HealthITAnalytics | February 10, 2020

A team of scientists from Purdue University and other research institutions around the world leveraged data mining techniques to better understand trends in the gene therapy field in respect to nonviral vectors. With the global gene therapy market expected to reach $13 billion by 2024, researchers are seeking to understand as much as they can about how these treatment can target cancer and other diseases. Purdue scientists joined forced with researchers from around the globe to learn more about the increasing number of worldwide patented innovations available for gene therapy treatment. The team focused specifically on nonviral methods, which use synthetic or natural compounds or physical forces to deliver materials that are generally less toxic than their viral counterparts into therapy treatments.

Spotlight

Cardinal Health has created a series of medical tools designed especially for nonprofessionals taking care of someone, or themselves, at home.

Spotlight

Cardinal Health has created a series of medical tools designed especially for nonprofessionals taking care of someone, or themselves, at home.

Related News

HEALTH TECHNOLOGY

Radius XR a new fashion-forward wearable technology brand brings together multimodal diagnostics practice management and patient engagement

Radius XR | October 03, 2022

IrisVision co-founder and CEO Ammad Khan today introduced a new company, Radius XR, to coincide with the opening of the American Academy of Ophthalmology 2022 meeting in Chicago. Radius XR builds on the therapeutic legacy of IrisVision by introducing diagnostic capability to the proprietary VR/AR assistive device. After the CES Award-winning 2017 launch of IrisVision, which has helped thousands of legally blind individuals see again, the company sought to leverage its core technology to benefit the eyecare industry by creating a patient-guided exam process that makes it easier and more affordable to diagnose a range of vision problems that are pervasive in the U.S. More than 32 million Americans aged 18+ are affected by vision loss, according to the IPUMS National Health Interview Survey1. Using a single Radius XR headset, patients can self-perform a range of vision tests that are clinically equivalent to gold standard exams. The exams currently performed with the Radius XR testing platform are Visual Field, Visual Acuity, Contrast Sensitivity, Amsler Grid, and Color Scheme. Development is ongoing. The shift to patient-guided testing enhances eyecare practice workflow and enables a single technician to administer several test sessions concurrently, doubling patient capacity. The fashion-forward design of Radius XR is a significant leap forward in wearable devices, with the look and feel of a pair of fashionable sunglasses. Radius XR is the industry’s lightest wearable device, weighing just under 6 oz., and features all-day battery life. The small, lightweight design overcomes the challenges of expensive and bulky legacy devices that force patients to sit in uncomfortable positions for testing. Exams can be conducted beyond exam lanes, allowing a patient’s exam in nontraditional spaces like waiting rooms, remote offices, and lobbies. With Radius XR, opportunities for greater accessibility and care are boundless. A breakthrough feature of the Radius XR platform is the immersive educational media library that can be tailored to each patient. This content is configured by each practice to display at an appropriate time during the exam experience automatically, eliminating the repetitive, time-consuming task of providing patients with educational information about their vision challenges while ensuring relevant information is consistently presented. The platform includes a Business Suite of management tools that streamline patient check-in, enable staff to customize the experience for multiple patients, and make it easier for eyecare professionals to manage business aspects critical to their practice's ongoing success. Trefethen named Radius XR CMO The launch of Radius XR is guided by John Trefethen, who joins the company as Chief Marketing Officer. Trefethen previously served in leadership roles at several medical device companies, including industry giants Zeiss Medical Technology and Topcon Healthcare. “Early diagnosis is the key to treating many conditions that can lead to vision loss. We believe a testing platform that combines a comfortable size with an engaging, immersive experience makes patients more likely to seek testing — and to be re-tested more frequently. Diagnosing conditions earlier and regularly tracking disease progression gives eyecare professionals an immense advantage in caring for their patients’ vision. Trefethen About Radius XR – RadiusXR The Radius XR platform is a portable vision diagnostic and patient engagement system that combines medical-grade diagnostics, business management, and patient education tools in a single wearable AR/VR device. The RadiusExam® proprietary algorithm provides diagnostic testing results equivalent to current exam gold standards, with the clinical science validated by Deming regression. As the algorithm presents stimuli to patients, Radius Adaptive® responds to maximize the algorithm's speed. The total hardware and software system helps medical professionals diagnose patients with accuracy, grow their eyecare practices, enhance patient engagement, and reduce staff workload by enabling patients to perform self-guided vision exams with minimal supervision. Radius XR builds on the therapeutic legacy of IrisVision, the first clinically validated wearable low vision solution. IrisVision was backed by a research grant from the National Eye Institute and developed in collaboration with researchers from top ophthalmology centers at Johns Hopkins University, Stanford University, and UPMC Pittsburg.

Read More

HEALTH TECHNOLOGY

IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

IQVIA | September 29, 2022

IQVIA a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc’s third-party validation demonstrates that IQVIA’s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. “At IQVIA, we are committed to delivering decentralized studies, we recognize the criticality of patient data protection in doing this and we understand the focus on data protection by European regulators,” said Ronan Brown, SVP and head of Patient Centric Solutions & Decentralized Trials. “IQVIA is proud to have this validation prove our longstanding dedication to data protection in decentralized trials.” TRUSTArc maps it’s GDPR Validation requirements to applicable GDPR Articles and ISO 27001 standards, alongside the standards of it’s own Privacy and Data Governance Accountability Framework. This validation is yet another step IQVIA has taken to enable DCTs to be brought to a wider group of participants, improving diversity, sustainability, and trust in clinical development. “Achieving a GDPR validation demonstrates IQVIA’s commitment to ensuring the highest standards of delivering decentralized studies to the people it serves. Organizations of all sizes must become privacy-forward to earn the trust of their customers. IQVIA has consistently prioritized being privacy-forward to earn the trust of their customers and the TRUSTArc GDPR and CCPA Validations reinforce that standing.” Chris Babel, CEO, TRUSTArc About IQVIA IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures.

Read More

HEALTH TECHNOLOGY

Perimeter Medical Imaging AI Announces Commercial Placement of Perimeter S-Series OCT within National Healthcare Provider System

Perimeter Medical Imaging AI, Inc. | September 30, 2022

Perimeter Medical Imaging AI, Inc. announced the commercial placement of its flagship Perimeter S-Series OCT system at a hospital that is part of a major national healthcare system and one of the largest healthcare networks in North Texas. Perimeter is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs. “This commercial placement of our Perimeter S-Series OCT system at a hospital in a major healthcare network marks a significant milestone for us as we gain traction validating our commercial model. Perimeter S-Series OCT aims to improve patient outcomes and lower healthcare costs, and we are excited that leading surgeons and hospitals are seeing the potential of our ground-breaking technology.” Jeremy Sobotta, Perimeter’s Chief Executive Officer About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level, with 10x greater image resolution than X-ray and ultrasound, and 100x greater than MRI. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company’s ticker symbol “PINK” is a reference to the pink ribbons displayed during Breast Cancer Awareness Month.

Read More